Stock Ratings / Health Care / RLYB / earnings

CRBP (47) RANI (36) INO (34) QUCY (35) ⌘ Pro Terminal →

Rallybio Corporation (RLYB) Next Earnings Date & Expected ±5.7% Move

$15.54 +0.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.53

Rallybio Corporation (RLYB) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $83.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RLYB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RLYB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Rallybio Corporation (NASDAQ: RLYB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $15.54 (+0.84% 1D, market cap $83.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RLYB ranks #615 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RLYB compare to CRBP and RANI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLYB carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CRBP (Corbus Pharmaceuticals Holdings Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $81.6M) and RANI (Rani Therapeutics Holdings Inc. (Class A)) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $84.4M). Among the 5-stock peer group, RLYB leads on earnings multiple (N/A) while RLYB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RLYB?

▼

Per RLYB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001739410), Rallybio Corporation generated $858.0K in revenue (+34.9% YoY), -$9.0M in net income, and -$29.8M in free cash flow against $62.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $15.53 (-0.04%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-9.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RLYB)Realized 20D OHLCV Swing Band: ±5.7%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY RLYB SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (35% of score)

FRED Regime × Technicals: 85% of 52W Range • RSI-14 at 40.4 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 4.13 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$16.79-2.6% Next Q

Q2 (-2Q)

Grade D$16.35+1.8% Next Q

Q3 (-1Q)

Grade D$16.65-6.7% Next Q

Current

Grade D-$15.54-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RLYB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RLYB currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.71) and Max Pain ($16.32) forces dealer call-delta covering toward $18.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RLYB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RLYB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±5.7% Swing Band

±$0.89 Expected Swing

MODEL EARNINGS SETUP GAUGE

RLYB Quantitative Pre-Earnings Setup: 37/100

Trailing EPS: $4.25 • YoY Revenue Growth: 34.9%

Model Bullish Setup (37/100)Model Risk Weight (63/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$858.0K	-$9.0M	-$29.8M	52%
FY 2024	2024-12-31	$636.0K	-$57.8M	-$49.3M	52%
FY 2023	2023-12-31	$0	-$74.6M	-$60.3M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RLYB)

✓Walkthrough of RLYB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RLYB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +10.06%🛡️ HOLDING TREND SUPPORT

2026-11-02O $15.91H $16.23L $15.54C $15.54VOL 40.1K

RES: $17.16SUP: $15.27SMA50: $16.71SMA200: $12.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RLYB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RLYB Butterfly Map → + Track RLYB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +34.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RLYB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RLYB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RLYB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RLYB)

Health Care Rank #615 of 1016 ⚔️ CRBP vs RLYB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RLYB vs. CRBP, RANI, INO, QUCY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rallybio Corporation (RLYB) ranks #615 by composite RQD confidence (37/100, grade D-) and #683 by equity capitalization ($83.0M). Within this direct 5-issuer industry benchmark cohort, RLYB leads on earnings valuation at N/A trailing P/E, while RLYB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CRBP currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with RLYB at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RLYB ACTIVE Rallybio Corporation	D-	37/100	—	—	-35.0%	+0.84%	$83.0M	Benchmark Subject
CRBP Corbus Pharmaceuticals Holdings Inc.	D	47/100	—	—	-35.0%	0.00%	$81.6M	/crbp-vs-rlyb →
RANI Rani Therapeutics Holdings Inc. (Class A)	D-	36/100	—	—	-35.0%	-2.54%	$84.4M	/rani-vs-rlyb →
INO Inovio Pharmaceuticals Inc.	E	34/100	—	—	-35.0%	-21.95%	$79.8M	/ino-vs-rlyb →
QUCY Quantum Cyber N.V.	D-	35/100	—	72.6%	-35.0%	-7.69%	$79.4M	/qucy-vs-rlyb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001739410

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rallybio Corporation (RLYB) reported GAAP revenue of $858.0K (+34.9% vs. FY2024 revenue of $636.0K ) , GAAP net income of -$9.0M, operating cash flow of -$29.8M, and free cash flow of -$29.8M (+39.5% YoY). On the balance sheet, RLYB closed FY2025 with $62.3M in total assets against $0 in total debt (Altman Z-Score: 4.13, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$858.0K	-$9.0M	-$29.8M	-$29.8M	$62.3M	—
FY2024 (FY)	2024-12-31	$636.0K	-$57.8M	-$49.3M	-$49.3M	$68.1M	—
FY2023 (FY)	2023-12-31	$0	-$74.6M	-$60.3M	-$60.3M	—	—

3. RLYB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RLYB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RLYB compare to CRBP and RANI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RLYB?

Where is RLYB trading relative to its 50-day, 200-day, and 52-week technical levels?

RLYB last traded at $15.54 (+0.84% on volume of 61,724 shares), positioning the stock -7.00% below its 50-day simple moving average ($16.71) and +19.72% above its 200-day simple moving average ($12.98). Across its 52-week range of $3.67 to $17.57, RLYB sits at the 85.4% percentile with a 14-day RSI of 40.4 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($14.65 to $16.43).

RLYB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is RLYB's next earnings date?

Based on SEC filing cadence, Rallybio Corporation (RLYB)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is RLYB stock expected to move on earnings?

Volatility modeling currently projects a ±5.7% event move for RLYB, spanning a range between $14.65 and $16.43.

Direct Sub-Reports: RLYB RQD Cockpit RLYB 12M Forecast RLYB Earnings & Move RLYB Dividends & DRIP RLYB Insiders & 13F RLYB Whale Options RLYB Profit Sankey RLYB News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RLYB — Rallybio Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:44:51Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD Score is 37, graded D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow" (per the Roarable RQD rating). The five pillars are:

Fundamental Cash Engine: 4 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, the core issue is that the company is not generating cash returns on capital; any upside thesis must rest on future events rather than current earnings power.
Whale 13F Flow: 7 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is weak, indicating limited evidence of sustained institutional conviction in the source data.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. The lowest pillar score here suggests insider activity in the source data does not provide a supportive signal.
Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. This is the strongest pillar, but it reflects market-relative positioning rather than company-specific strength.
Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 4.13, Piotroski F is 3/9, and Debt/Equity is 0.5. The Altman Z reading is comparatively supportive, while the Piotroski F-Score of 3/9 signals weak fundamental quality.

Valuation tradeoffs are difficult to assess because P/E, EPS, and EV/EBITDA are not available in source data. The absence of earnings multiples means a prospective investor cannot benchmark the price of $15.41 against profitability. Upside drivers, as far as the source data shows, depend on catalysts (see Recent Catalysts) rather than on current cash generation.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.9M	$-33.1M	$-9.0M	N/A	$-29.8M	$31.4M	N/A
FY 2024	$0.6M	$-60.5M	$-57.8M	N/A	$-49.3M	$13.9M	N/A
FY 2023	$0.0M	$-78.9M	$-74.6M	N/A	$-60.3M	N/A	N/A

Per the SEC financials and market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -35%. Reported net loss narrowed from $-57.8M in FY 2024 to $-9.0M in FY 2025, while cash rose from $13.9M to $31.4M. Per the Roarable RQD rating, the Altman Z-Score is 4.13 and the Piotroski F-Score is 3/9. Debt/Equity is 0.5 per the Roarable RQD rating, though reported debt figures are N/A in the SEC financials.

Recent Catalysts & News Wire Analysis

Source headlines reference several items, all tagged to RLYB:

A SEC Form 4 filing by Rallybio Corporation (catalyst tag).
A CFO sale of 599 shares at $16.04 to cover vesting taxes (catalyst tag).
A Business Wire investor alert stating that Kahn Swick & Foti, LLC is investigating the merger of Rallybio Corporation (catalyst tag).
A TradingView headline attributing a 9M profit to a $50.0M termination fee as the Avenzo merger advanced (market wire tag, the only yellow-flagged item).
A Form 4 filing by director Christine A. Nash dated 28 October (catalyst tag).
A SEC filing dated Oct 16, 2026 (catalyst tag).

Risk watch items are the merger-related investigation notice and the termination-fee headline, which is flagged yellow. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Open Questions

What are the company's products, pipeline, and revenue sources, given that the profile and financials do not describe them?
What is the status and terms of the Avenzo merger, and what does the $50.0M termination fee mean for remaining shareholders?
What are the debt levels, given that reported debt is N/A while Debt/Equity is cited at 0.5?
What is the company's cash runway at the FY 2025 burn rate of $-29.8M in FCF, against $31.4M in cash?
Why are EPS and valuation multiples absent, and what would a fair-value reference look like?

RLYB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rallybio Corporation (RLYB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RLYB Debate Forum (3) ↓

🟢 CATALYST Quantisnow • 1h ago

SEC Form 4 filed by Rallybio Corporation

Quantisnow report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 4h ago

To cover vesting taxes, Rallybio (RLYB) CFO sells 599 shares at $16.04.

Stock Titan report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Business Wire • 7h ago

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

Business Wire report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 10h ago

RLYB: A $50.0M termination fee drove 9M profit as the Avenzo merger advanced

TradingView report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com South Africa • 13h ago

Form 4 Rallybio Corp: Christine A. Nash (Director) For: 28 October By Investing.com

Investing.com South Africa report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 16h ago

Rallybio Corp SEC Filing (Oct 16, 2026)

Stock Titan report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 19h ago

Rallybio (RLYB) Edges Up 0.35% to $16.99, Sitting Midway Between Key Support and Resistance - Volume Profile

https://www.siam.in/ report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 22h ago

A November 4 stockholder vote stands between Rallybio (RLYB) holders and a special cash payout.

Stock Titan report covering Rallybio Corporation (RLYB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RLYB Bull vs. Bear Conversation Board — What's Your Call at $15.54?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RLYB 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $13.56 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RLYB (D- • RQD 37/100) a Buy at $15.41?

Welcome to the RLYB (Rallybio Corporation) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $12.02 (-22.0%)

Spot @ $15.41

Pump the brakes on RLYB — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RLYB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Rallybio Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $18.49 (+20.0%)

Spot @ $15.41

RLYB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RLYB, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $15.41 (52-wk range $13.41 - $16.80), any beat on forward guidance forces shorts and underweight funds to chase.